CD33 and neoplasm: In another experiment from that same study, NSG-S mice that retained myeloid cells after receiving CD33 KO CD34+ cells and a CD33 directed CAR, experienced greater reduction in tumor burden and less toxicity compared to mice that loss myeloid cells after receiving control CD34+ cells [37].